Media coverage about Atossa Genetics (NASDAQ:ATOS) has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Atossa Genetics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.568496396263 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Atossa Genetics (NASDAQ:ATOS) traded down $0.01 during trading hours on Friday, hitting $0.33. 656,200 shares of the stock traded hands, compared to its average volume of 1,350,097. Atossa Genetics has a 12-month low of $0.31 and a 12-month high of $2.60.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/01/atossa-genetics-atos-earns-media-sentiment-score-of-0-11.html.

About Atossa Genetics

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Insider Buying and Selling by Quarter for Atossa Genetics (NASDAQ:ATOS)

Receive News & Stock Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related stocks with our FREE daily email newsletter.